pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

25,783 catalysts · 6,075 approval · 5,000 device 510k · 4,728 grant · 3,189 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 82 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2022-04-29×clear all
type
  • approval6,075
  • device 510k5,000
  • grant4,728
  • 8k filing3,189
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings584
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Dec 12, 2022

    5
    ›Dec 16, 2022approval1336d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›Dec 16, 2022approval1336d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: LANNETT CO INC. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›Dec 16, 2022approval1336d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Dec 16, 2022approval1336d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: ACTAVIS ELIZABETH. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›Dec 16, 2022approval1336d agoVRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalCARIPRAZINE HYDROCHLORIDE

    Sponsor: ABBVIE. Form: CAPSULE. Route: ORAL

    full page →CARIPRAZINE HYDROCHLORIDE →fda approvals ↗

    Week of Dec 19, 2022

    27
    ›Dec 19, 2022approval1333d agoOZURDEX (DEXAMETHASONE) — FDA approvaldexamethasone LA

    Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL

    full page →dexamethasone LA →fda approvals ↗
    ›Dec 19, 2022approval

    Week of Dec 26, 2022

    1
    ›Dec 28, 2022approval1324d agoBRIUMVI (UBLITUXIMAB-XIIY) — FDA approvalublituximab

    Sponsor: TG THERAPEUTICS, INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →ublituximab →fda approvals ↗

    Week of Jan 2, 2023

    5
    ›Jan 3, 2023approval1318d agoFINTEPLA (FENFLURAMINE HYDROCHLORIDE) — FDA approvalfenfluramine hydrochloride

    Sponsor: UCB INC. Form: SOLUTION. Route: ORAL

    full page →fenfluramine hydrochloride →fda approvals ↗
    ›Jan 3, 2023approval

    Week of Jan 9, 2023

    4
    ›Jan 9, 2023approval1312d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Jan 11, 2023approval

    Week of Jan 16, 2023

    8
    ›Jan 17, 2023approval1304d agoMARINOL (DRONABINOL) — FDA approvalVertanical GmbH

    Sponsor: ALKEM LABS LTD. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 17, 2023approval
    ← prev
    page 12 of 516
    next →
    1333d ago
    CIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoCIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoCIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoCIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoCIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoCIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoCIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoCIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoCIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoCIPROFLOXACIN HYDROCHLORIDE — FDA approvalBayer HealthCare Pharmaceuticals Inc

    Sponsor: UNIQUE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoILUMYA (TILDRAKIZUMAB-ASMN) — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: SUN PHARMA GLOBAL. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Dec 19, 2022approval1333d agoALDACTAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: PFIZER. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Dec 19, 2022approval1333d agoALDACTONE (SPIRONOLACTONE) — FDA approvalALDACTONE

    Sponsor: PFIZER. Form: TABLET. Route: ORAL

    full page →ALDACTONE →fda approvals ↗
    ›Dec 21, 2022approval1331d agoMYCOPHENOLATE MOFETIL — FDA approvalMYCOPHENOLATE MOFETIL

    Sponsor: AMNEAL. Form: FOR SUSPENSION. Route: ORAL

    full page →MYCOPHENOLATE MOFETIL →fda approvals ↗
    ›Dec 21, 2022approval1331d agoMYCOPHENOLATE MOFETIL — FDA approvalMYCOPHENOLATE MOFETIL

    Sponsor: AMNEAL. Form: FOR SUSPENSION. Route: ORAL

    full page →MYCOPHENOLATE MOFETIL →fda approvals ↗
    ›Dec 21, 2022approval1331d agoRUBRACA (RUCAPARIB CAMSYLATE) — FDA approvalrucaparib camsylate

    Sponsor: PHARMAAND. Form: TABLET. Route: ORAL

    full page →rucaparib camsylate →fda approvals ↗
    ›Dec 21, 2022approval1331d agoACTEMRA (TOCILIZUMAB) — FDA approvaltocilizumab

    Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

    full page →tocilizumab →fda approvals ↗
    ›Dec 21, 2022approval1331d agoACTEMRA (TOCILIZUMAB) — FDA approvaltocilizumab

    Sponsor: GENENTECH. Form: INJECTABLE. Route: INTRAVENOUS, SUBCUTANEOUS

    full page →tocilizumab →fda approvals ↗
    ›Dec 22, 2022approval1330d agoSUNLENCA (LENACAPAVIR SODIUM) — FDA approvallenacapavir sodium LA

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →lenacapavir sodium LA →fda approvals ↗
    ›Dec 22, 2022approval1330d agoSUNLENCA (LENACAPAVIR SODIUM) — FDA approvallenacapavir sodium LA

    Sponsor: GILEAD SCIENCES INC. Form: TABLET. Route: ORAL

    full page →lenacapavir sodium LA →fda approvals ↗
    ›Dec 22, 2022approval1330d agoWAKIX (PITOLISANT HYDROCHLORIDE) — FDA approvalpitolisant hydrochloride

    Sponsor: HARMONY. Form: TABLET. Route: ORAL

    full page →pitolisant hydrochloride →fda approvals ↗
    ›Dec 22, 2022approval1330d agoLUNSUMIO (MOSUNETUZUMAB-AXGB) — FDA approvalmosunetuzumab

    Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

    full page →mosunetuzumab →fda approvals ↗
    ›Dec 22, 2022approval1330d agoOLPRUVA (SODIUM PHENYLBUTYRATE) — FDA approvalSODIUM PHENYLBUTYRATE

    Sponsor: ACER. Form: FOR SUSPENSION. Route: ORAL

    full page →SODIUM PHENYLBUTYRATE →fda approvals ↗
    ›Dec 22, 2022approval1330d agoCIMZIA (CERTOLIZUMAB PEGOL) — FDA approvalcertolizumab pegol

    Sponsor: UCB INC. Form: INJECTABLE. Route: INJECTION

    full page →certolizumab pegol →fda approvals ↗
    ›Dec 23, 2022approval1329d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Dec 23, 2022approval1329d agoHADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →HADLIMA →fda approvals ↗
    1318d ago
    MIFEPREX (MIFEPRISTONE) — FDA approvalCORCEPT THERAPEUTICS INC

    Sponsor: DANCO LABS LLC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 3, 2023approval1318d agoMIFEPRISTONE — FDA approvalMIFEPRISTONE

    Sponsor: GENBIOPRO. Form: TABLET. Route: ORAL

    full page →MIFEPRISTONE →fda approvals ↗
    ›Jan 6, 2023approval1315d agoLEQEMBI (LECANEMAB-IRMB) — FDA approvallecanemab

    Sponsor: EISAI INC. Form: INJECTABLE. Route: INJECTION

    full page →lecanemab →fda approvals ↗
    ›Jan 6, 2023approval1315d agoSUBLOCADE (BUPRENORPHINE) — FDA approvalbuprenorphine LA

    Sponsor: INDIVIOR. Form: SOLUTION, EXTENDED RELEASE. Route: SUBCUTANEOUS

    full page →buprenorphine LA →fda approvals ↗
    1310d ago
    BALVERSA (ERDAFITINIB) — FDA approvalerdafitinib

    Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

    full page →erdafitinib →fda approvals ↗
    ›Jan 12, 2023approval1309d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 13, 2023approval1308d agoRYKINDO (RISPERIDONE) — FDA approvalDelpor Inc

    Sponsor: SHANDONG LUYE. Form: FOR SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    1304d ago
    CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE (AMITRIPTYLINE HYDROCHLORIDE) — FDA approvalAlgoTherapeutix SAS

    Sponsor: TP ANDA HOLDINGS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 17, 2023approval1304d agoCHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE (AMITRIPTYLINE HYDROCHLORIDE) — FDA approvalAlgoTherapeutix SAS

    Sponsor: TP ANDA HOLDINGS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 17, 2023approval1304d agoTRAMADOL HYDROCHLORIDE — FDA approvalTrigen Laboratories Inc

    Sponsor: IPCA LABS LTD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 17, 2023approval1304d agoTRAMADOL HYDROCHLORIDE — FDA approvalTrigen Laboratories Inc

    Sponsor: IPCA LABS LTD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 17, 2023approval1304d agoTRAMADOL HYDROCHLORIDE — FDA approvalTrigen Laboratories Inc

    Sponsor: IPCA LABS LTD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 17, 2023approval1304d agoTRAMADOL HYDROCHLORIDE — FDA approvalTrigen Laboratories Inc

    Sponsor: IPCA LABS LTD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 17, 2023approval1304d agoTRAMADOL HYDROCHLORIDE — FDA approvalTrigen Laboratories Inc

    Sponsor: IPCA LABS LTD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    $ABBV248.14-0.78%
    $ABBV248.14-0.78%
    $TGTX49.50-0.80%
    $AMRX17.52+2.43%
    $PFE26.26-1.36%
    $PFE26.26-1.36%
    $AMRX17.52+2.43%
    $GILD135.56-0.15%
    $AMRX17.52+2.43%
    $GILD135.56-0.15%
    $HRMY39.77+0.63%
    $INDV38.73+0.78%
    $CORT112.18+0.29%